PDCD1 and cancer: Multiple studies from the Asia–Pacific region indicated a HBVr risk of around 14% (range 11–17%) in HBsAg-positive cancer patients receiving PD-1 inhibitors but not NAs (Lee, et al. 2020; Zhang, et al. 2019; Papatheodoridis et al. 2022).